COMP <GO>
KRMD vs MRK // GROSS PROFIT MARGIN
KORU Medical Systems Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: KRMD 3
— MRK 7
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $2.99 (-7.43%) • MKT CAP: $149.1M
gross-margins
62.30%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 62.30% | 74.80% | -12.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.70% | 20.70% | -49.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.31% | 3.42% | -3.11 | MRK | /fcf-yield <GO> |
| Operating Margin | -7.20% | 34.30% | -41.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | -6.40% | 28.10% | -34.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 22.20% | 1.30% | +20.90 | KRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.05 | 5.19 | +2.86 | KRMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.8 | 51.7 | +4.10 | KRMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $149.1M | $361.02B | -$360.87B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRMD REV | MRK REV | KRMD GROSS % | MRK GROSS % | KRMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $41.1M | $65.01B | 62.3% | 74.8% | $462.4K | $12.36B |
| FY 2024 | $33.6M | $64.17B | 63.4% | 76.3% | -$319.7K | $18.10B |
| FY 2023 | $28.5M | $60.12B | — | — | -$4.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRMD // BETA —
MRK // BETA 0.92